# Immature leukocyte and plasma-induced cell death reveal subclinical immune activation in EGPA patients in remission

**Authors:** Chiara Baggio, Luca Iorio, Carlotta Boscaro, Federica Davanzo, Veronica Davanzo, Michela Pelloso, Marta Tonello, Paolo Sfriso, Mattia Albiero, Roberta Ramonda, Andrea Doria, Roberto Padoan, Francesca Oliviero

PMC · DOI: 10.1007/s00011-026-02189-7 · Inflammation Research · 2026-02-02

## TL;DR

This study finds that even when in remission, EGPA patients show hidden immune activity, with their plasma causing immune cell death and inflammation in healthy donors.

## Contribution

The study reveals subclinical immune activation in EGPA patients during remission through plasma-induced effects on healthy donor immune cells.

## Key findings

- AAV patients in remission show increased immature neutrophils.
- Plasma from ANCA-positive EGPA patients induces PBMC death and cytokine release.
- Conditioned media enhances immune cell migration in a cytokine-dependent manner.

## Abstract

ANCA-associated vasculitis (AAV) is a group of rare autoimmune diseases characterized by pauci-immune necrotizing inflammation of small to medium-sized blood vessels, in which ANCAs targeting neutrophil antigens promote neutrophil activation, endothelial injury and organ damage. Although AAV follows a relapsing-remitting course, the immune landscape during remission remains poorly defined. This study investigated leukocyte alterations across AAV subtypes and examined whether plasma from ANCA-positive and ANCA-negative eosinophilic granulomatosis with polyangiitis (EGPA) patients in remission modulates peripheral blood mononuclear cell (PBMC) responses in healthy donors (HDs).

Peripheral blood was collected from 62 AAV patients in remission and 28 age- and sex-matched HDs. Leukocyte morphology was assessed via May-Grünwald Giemsa staining. Circulating cytokines and chemokines were quantified by ELISA. HD-derived PBMCs were exposed to plasma from EGPA patients, antiphospholipid-positive controls, or HDs. Cell death, metabolic activity, and cytokine production were evaluated using Trypan Blue, Annexin V/PI staining, MTT assays, and ELISA. Chemotaxis assays assessed cell migration in response to conditioned media, with or without Anakinra or CCR1 inhibitor J113863.

AAV patients showed increased immature neutrophils. Plasma from ANCA-positive EGPA patients induced PBMC death, inflammasome-related cytokine release, and secretion of chemotactic and proangiogenic factors. Conditioned media enhanced immune cell migration in a cytokine-dependent manner.

These findings indicate persistent subclinical immune activation during AAV remission, particularly in ANCA-positive EGPA, suggesting a role for mononuclear cell-mediated inflammation in relapse risk and the potential utility of immune monitoring.

The online version contains supplementary material available at 10.1007/s00011-026-02189-7.

## Linked entities

- **Diseases:** ANCA-associated vasculitis (MONDO:0012105), eosinophilic granulomatosis with polyangiitis (MONDO:0015943), antiphospholipid syndrome (MONDO:0017278)

## Full-text entities

- **Genes:** ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, MPO (myeloperoxidase) [NCBI Gene 4353], CCR1 (C-C motif chemokine receptor 1) [NCBI Gene 1230] {aka CD191, CKR-1, CKR1, CMKBR1, HM145, MIP1aR}, PRTN3 (proteinase 3) [NCBI Gene 5657] {aka ACPA, AGP7, C-ANCA, CANCA, MBN, MBT}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, CCL23 (C-C motif chemokine ligand 23) [NCBI Gene 6368] {aka CK-BETA-8, CKb8, Ckb-8, Ckb-8-1, MIP-3, MIP3}, IL18BP (interleukin 18 binding protein) [NCBI Gene 10068] {aka FVH, IL18BPa}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, IL5 (interleukin 5) [NCBI Gene 3567] {aka EDF, IL-5, TRF}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}
- **Diseases:** neutrophil (MESH:C564275), organ damage (MESH:D000092124), granulomatosis (MESH:D015267), dysregulation (MESH:D021081), endothelial injury (MESH:D057772), necrosis (MESH:D009336), MPA (MESH:D055953), HD (MESH:D006816), glomerulonephritis (MESH:D005921), Vasculitis (MESH:D014657), eosinophilic granulomatosis (MESH:D017681), eosinophilic inflammation (MESH:D007249), HD (MESH:D000067329), EGPA (MESH:D014890), autoimmune diseases (MESH:D001327), AAV (MESH:D056648), infection (MESH:D007239), aPL (MESH:D016736), nuclear abnormalities (MESH:C563333), Anti (MESH:D006679), LDH (MESH:C538133), malignancy (MESH:D009369), nuclear (MESH:C564596), eosinophilia (MESH:D004802), asthma (MESH:D001249), Cytotoxicity (MESH:D064420), peripheral neuropathy (MESH:D010523)
- **Chemicals:** PI (MESH:D011419), streptomycin (MESH:D013307), EDTA (MESH:D004492), DMSO (MESH:D004121), MGG (MESH:C043260), rituximab (MESH:D000069283), penicillin (MESH:D010406), reactive oxygen species (MESH:D017382), FITC (MESH:D016650), 3-[4,5 dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MESH:C022616), eosin (MESH:D004801), methotrexate (MESH:D008727), PBS (MESH:D007854), MTT (MESH:C070243), LPS (MESH:D008070), Trypan Blue (MESH:D014343), heparin (MESH:D006493), cyclophosphamide (MESH:D003520), mycophenolate mofetil (MESH:D009173), PI (MESH:D010716), NA (MESH:D012964), J113863 (MESH:C413447), CyQUANT (-), formazan (MESH:D005562), glutamine (MESH:D005973)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12862012/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12862012/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12862012/full.md

---
Source: https://tomesphere.com/paper/PMC12862012